CryoLife (CRY) Claims Victory in Lawsuit vs. Medafor
Tweet Send to a FriendGet Alerts CRY Hot Sheet
Price: $6.21 --0%
Overall Analyst Rating:
NEUTRAL (
Up)
Dividend Yield: 1.6%
Revenue Growth %: +9.9%
Overall Analyst Rating:
NEUTRAL (
Up)Dividend Yield: 1.6%
Revenue Growth %: +9.9%
Trade CRY Now!
CryoLife, Inc. (NYSE: CRY) has reached full settlement of the outstanding CryoLife, Inc. v. Medafor, Inc. lawsuit that was pending in the Northern District Court of Georgia.
Under terms of the settlement, Medafor has agreed to pay CryoLife $3.5 million in cash. Fifty percent of the payment is to be paid on or before July 9, 2012 and the remainder on or before September 6, 2012.
In addition, as part of the settlement, CryoLife will no longer be required to pay Medafor $1.17 million for previous purchases of inventory, for which Medafor had requested payment. Both parties have agreed to dismiss with prejudice all claims and counter claims associated with the lawsuit. CryoLife will continue to own approximately 2.39 million shares of Medafor common stock, which CryoLife estimates at approximately 9.2% of Medafor's total outstanding shares. CryoLife believes that it remains Medafor's largest shareholder. Although the terms of the settlement are binding, the parties are in the process of formalizing a settlement agreement.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Under terms of the settlement, Medafor has agreed to pay CryoLife $3.5 million in cash. Fifty percent of the payment is to be paid on or before July 9, 2012 and the remainder on or before September 6, 2012.
In addition, as part of the settlement, CryoLife will no longer be required to pay Medafor $1.17 million for previous purchases of inventory, for which Medafor had requested payment. Both parties have agreed to dismiss with prejudice all claims and counter claims associated with the lawsuit. CryoLife will continue to own approximately 2.39 million shares of Medafor common stock, which CryoLife estimates at approximately 9.2% of Medafor's total outstanding shares. CryoLife believes that it remains Medafor's largest shareholder. Although the terms of the settlement are binding, the parties are in the process of formalizing a settlement agreement.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Ackman's Pershing Square Says Herbalife (HLF) Refuses to Release Sales Data, Calls for Probe
- Genetic Tech (GENE) Updates on Impact of SCOTUS Ruling on Gene Patenting
- Sprint (S), SoftBank Call on FCC to Push Deal Through
Create E-mail Alert Related Categories
Litigation
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
